Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IMI Funding rules set to change to benefit SMEs and biotechs

This article was originally published in Scrip

Executive Summary

The €2 billion European Commission-EFPIA backed Innovative Medicines Initiative (IMI) will be changing its funding rules to benefit SMEs, biotech firms and universities, after these bodies criticised the IMI's lack of alignment with FP7 rules which had worked against them.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC010951

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel